Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Discovery of a Novel HDAC3 Selective Inhibitor and its Evaluation in Lymphoma Model
- Authors
- Choi, Chang-Ju; Kim, Mira; Han, Sun Young; Jeon, Jiyoung; Lee, Jae Ho; Oh, Jeong-In; Suh, Kwee Hyun; Suh, Dong-Churl; Lee, Kwang-Ok
- Issue Date
- Jan-2016
- Publisher
- WILEY-V C H VERLAG GMBH
- Keywords
- HDAC3 selective inhibitor; Lymphoma model
- Citation
- BULLETIN OF THE KOREAN CHEMICAL SOCIETY, v.37, no.1, pp 42 - 47
- Pages
- 6
- Journal Title
- BULLETIN OF THE KOREAN CHEMICAL SOCIETY
- Volume
- 37
- Number
- 1
- Start Page
- 42
- End Page
- 47
- ISSN
- 0253-2964
1229-5949
- Abstract
- Histone deacetylase (HDAC) inhibition is a potentially attractive approach to cancer therapy. A number of HDAC inhibitors are in clinical development stages for the treatment of cancer as well as immune and inflammatory disorders. Although there are several approved HDAC inhibitors by the US FDA, they show a broad inhibitory spectrum against HDAC subfamily. Herein, we synthesized a series of novel hydroxamate analogs, and evaluated them with lymphoma cancer cell. Conclusively, we identified an HDAC3 selective inhibitor which shows good anticancer activity for the lymphoma model, as well as a good drug metabolism and pharmacokinetics (DMPK) profile.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.